Alpha-Lipoic Acid (ALA) vs FOXO4-DRI
A side-by-side research comparison of Alpha-Lipoic Acid (ALA) and FOXO4-DRI across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Alpha-Lipoic Acid (ALA) | FOXO4-DRI |
|---|---|---|
| Full name | R-Alpha-Lipoic Acid Injectable | FOXO4-D-Retro-Inverso Peptide (Senolytic) |
| Category | Anti-Aging | Anti-Aging |
| Status | Supplement / Compounded injectable | Research compound |
| Mechanism | Regenerates glutathione, vitamin C, and vitamin E. Chelates heavy metals. Acts as cofactor for mitochondrial enzyme complexes. Activates Nrf2 pathway for endogenous antioxidant production. | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. |
| Molecular weight | 206.33 Da | ~4,500 Da |
| Half-life | ~30 minutes (oral); longer IM | 12-24 hours (D-amino acid stability) |
| Bioavailability | ~30% oral; ~100% injectable | Moderate (SubQ) |
| Typical dose | 200-600 mg | 5-10 mg/kg (animal studies) |
| Frequency | 1-3x per week (injectable) | 3x per week for 3 weeks |
| Route | IV/IM injection or oral capsule | Subcutaneous |
Alpha-Lipoic Acid (ALA) reported benefits
- Universal antioxidant
- Neuropathy relief
- Heavy metal chelation
- Blood sugar regulation
- Glutathione recycling
- Liver protection
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Related comparisons
Research and educational reference only. Not medical advice.